At a Glance
- Company: Johnson & Johnson
- Location: New Brunswick, New Jersey, USA
- Deal value: Undisclosed discounts; tariff exemption on branded imports; part of $55bn US manufacturing pledge
- Focus area: Most Favored Nation (MFN) pricing for cash‑pay patients via TrumpRx.gov; US onshoring
- Next steps: Build new facilities in Pennsylvania and North Carolina
What happened?
Johnson & Johnson has signed a voluntary Most Favored Nation (MFN) drug pricing agreement with the Trump administration, committing to lower prices on unspecified branded medicines sold to cash‑pay patients through TrumpRx.gov. In exchange, J&J gains exemption from 100% tariffs on imported branded pharmaceuticals threatened since April 2025.
Why does it matter?
The deal is the 15th MFN pact in a wave started by Pfizer and AstraZeneca in October 2025, followed by nine majors in December, leaving only AbbVie and Regeneron among 17 targeted firms without agreements (though talks continue). GlobalData analysts argue MFN price concessions can only be sustained by shifting away from import reliance, accelerating onshoring to protect margins and supply chains.
Who’s behind it?
J&J is a global pharma leader investing $55bn in US manufacturing, including $2bn in a Fujifilm Biotechnologies CDMO site in North Carolina for cell culture biologics. The Trump administration’s MFN policy uses tariff threats to enforce price alignment with other wealthy markets via TrumpRx.gov.
How was it achieved?
J&J will offer MFN‑level discounts on select branded drugs through the federal DTC platform, gaining tariff immunity in return. Simultaneously, it announced two new US sites—a Pennsylvania cell therapy facility and North Carolina drug product plant—to align with policy demands.
What’s next?
J&J will operationalise the pricing commitments and advance its $55bn US manufacturing build‑out, potentially setting a template for remaining holdouts. Globally, similar trends emerge, like EU Critical Medicines Act reforms for domestic production and stockpiling.
What are people saying?
GlobalData’s Janet Beal described the shift as “balancing global competitiveness amid shifting policy and trade dynamics”. Analysts view J&J’s deal as a “structural shift” linking pricing to policy stability, reinforcing onshoring as pharma’s strategic response.